IMMUNIC, INC. Stockholders Elect Directors, Ratify Auditors

TL;DR

IMMUNIC stockholders re-elected directors and kept PwC as auditor. Board and auditor confirmed.

AI Summary

On June 11, 2024, IMMUNIC, INC. filed an 8-K to report the results of its Annual Meeting of Stockholders held on June 11, 2024. The company announced that its stockholders voted to approve the election of two Class II directors, Dr. Daniel G. Welch and Mr. David M. E. Smith, to serve until the 2027 annual meeting. Additionally, stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.

Why It Matters

This filing confirms the composition of IMMUNIC's board of directors and its auditor for the upcoming fiscal year, providing clarity on corporate governance and financial oversight.

Risk Assessment

Risk Level: low — The filing reports routine corporate governance matters, such as director elections and auditor ratification, which typically carry low risk.

Key Players & Entities

• IMMUNIC, INC. (company) — Registrant
• Dr. Daniel G. Welch (person) — Elected Class II Director
• Mr. David M. E. Smith (person) — Elected Class II Director
• PricewaterhouseCoopers LLP (company) — Independent Registered Public Accounting Firm
• June 11, 2024 (date) — Date of Annual Meeting and Earliest Event Reported
• 2027 (date) — Term end for elected directors
• December 31, 2024 (date) — Fiscal year end for auditor ratification

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 IMUX The Nasdaq Stock Market LLC In
• $0 — er of shares of common stock, par value $0.0001, entitled to vote at the Meeting w

Filing Documents

• e663709_8k-immunic.htm (8-K) — 25KB
• 0001193805-24-000791.txt ( ) — 195KB
• imux-20240611.xsd (EX-101.SCH) — 3KB
• imux-20240611_lab.xml (EX-101.LAB) — 33KB
• imux-20240611_pre.xml (EX-101.PRE) — 22KB
• e663709_8k-immunic_htm.xml (XML) — 4KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. On June 11, 2024, Immunic, Inc. (the " Company ") held its annual meeting of stockholders (the " Meeting "). The total number of shares of common stock, par value $0.0001, entitled to vote at the Meeting was 90,079,016, and there were present at the Meeting, in person or by proxy, 59,921,013 shares, which constituted a quorum for the Meeting. At the Meeting, the stockholders voted: (1) to elect Dr. Daniel Vitt and Dr. Duane Nash as Class I directors, serving until the Company's 2027 annual meeting of stockholders and until their respective successors are duly elected and qualified; (2) to ratify the selection of Baker Tilly US, LLP (" Baker Tilly ") as the Company's independent registered public accounting firm, for the fiscal year ending December 31, 2024; and (3) to approve, by non-binding advisory vote, the resolution approving the Company's named executive officer compensation (" Say on Pay Proposal "). The final results of the stockholders' votes at the Meeting are set forth below: Proposal 1: Election of Class I Directors NOMINEE FOR WITHHELD Dr. Daniel Vitt 43,559,455 6,322,678 Dr. Duane Nash 43,433,233 6,448,900 Proposal 2: Ratification of Appointment of Baker Tilly as Independent Registered Public Accounting Firm FOR AGAINST ABSTAIN BROKER NON-VOTES 59,535,850 281,381 103,782 0 Proposal 3: Approval, By Non-Binding Advisory Vote, of Say on Pay Proposal FOR AGAINST ABSTAIN 47,604,179 2,218,350 59,604

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. Dated: June 12, 2024 Immunic, Inc. By: /s/ Daniel Vitt Daniel Vitt President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR